Kurzfassung

Metronomic chemotherapy is an attractive therapeutic option in advanced breast cancer. This prospective phase II trial examines efficacy as wellas toxicity of daily oral vinorelbine (30 mg)in patients with hormone-receptor positive and HER2 negative advanced breast cancer resistent to endocrine therapy. Additionally, an ambitious translational research is conducted to elucidate both the anti-angiogenic and immuno-stimulating potential of metronomic low-dose vinorelbine in breast cancer.